Stock That Is Worth Exploring Now: CVS Health Corp (NYSE: CVS)

CVS Health Corp (NYSE:CVS) does about 10.91M shares in volume on a normal day but saw 9225692 shares change hands in Friday’s trading. The company now has a market cap of 70.07B USD. Its current market price is $55.82, marking an increase of 0.25% compared to the previous close of $55.68. The 52 week high reached by this stock is $83.25 whilst the lowest price level in 52 weeks is $53.70.

CVS Health Corp (CVS) has a 20-day trading average at $63.34 and the current price is -32.95% off the 52-week high compared with 3.95% distance from its 52-week low. The 50-day simple moving average of the closing price is $70.69 and its 200-day simple moving average is $71.91. If we look at the stock’s price movements over the week, volatility stands at 2.08%, which increases to 2.26% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 19.81 to suggest the stock is oversold.

The consensus objective for the share price is $70.54, suggesting that the stock has a potential upside of 20.87% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 07, 2024 when TD Cowen downgraded the stock to “Hold” and issued a price target of between $99 and $59. UBS also downgraded the stock to “Neutral” from Buy on May 02, 2024 at a price target of $85-$60. Leerink Partners downgraded its price target at $87-$60.

CVS Health Corp (CVS) stock is down -0.14% over the week and -19.96% over the past month. Its price is -29.31% year-to-date and -19.93% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of 2.21 above consensus estimates by 0.1. The company’s next earnings report forecasts estimating quarterly EPS at 1.77 and 7.0 for whole year. Expected sales for next quarter are $92.36B, which analysts say will come at $368.8B for the current fiscal year and next year at $387.57B. In addition, estimates put the company’s current quarterly revenue at an average of $91.53B.

To reach the target analysts have set, the stock logically needs to grow 20.87 percent from here.

The company has a return on investment of 4.97% and return on equity of 10.07%. The price to earnings ratio (P/E ratio) amounts to 9.81 while the forward price to earnings ratio is 7.06. The beta has a value of 0.52. Price to book ratio is 0.94 and price to sales ratio is 0.19.